CliffBio
small molecule

ALENDRONATE SODIUM

ALENDRONATE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameALENDRONATE SODIUM
Active ingredientALENDRONATE SODIUM
StrengthEQ 35MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2008
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ALENDRONATE SODIUM patent cliff — loss of exclusivity — | CliffBio